KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Xenon Pharmaceuticals (XENE) Invested Capital (2016 - 2025)

Historic Invested Capital for Xenon Pharmaceuticals (XENE) over the last 13 years, with Q3 2025 value amounting to $559.5 million.

  • Xenon Pharmaceuticals' Invested Capital fell 2986.89% to $559.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $559.5 million, marking a year-over-year decrease of 2986.89%. This contributed to the annual value of $754.9 million for FY2024, which is 1864.58% down from last year.
  • As of Q3 2025, Xenon Pharmaceuticals' Invested Capital stood at $559.5 million, which was down 2986.89% from $634.0 million recorded in Q2 2025.
  • In the past 5 years, Xenon Pharmaceuticals' Invested Capital ranged from a high of $927.9 million in Q4 2023 and a low of $248.9 million during Q3 2021
  • In the last 5 years, Xenon Pharmaceuticals' Invested Capital had a median value of $686.9 million in 2023 and averaged $642.9 million.
  • As far as peak fluctuations go, Xenon Pharmaceuticals' Invested Capital surged by 22099.03% in 2021, and later crashed by 2986.89% in 2025.
  • Over the past 5 years, Xenon Pharmaceuticals' Invested Capital (Quarter) stood at $550.0 million in 2021, then soared by 31.17% to $721.5 million in 2022, then rose by 28.61% to $927.9 million in 2023, then decreased by 18.65% to $754.9 million in 2024, then dropped by 25.88% to $559.5 million in 2025.
  • Its Invested Capital stands at $559.5 million for Q3 2025, versus $634.0 million for Q2 2025 and $704.0 million for Q1 2025.